search
Back to results

Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood. (OBEGEN)

Primary Purpose

Obesity, Child

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
sequencing of a panel of 14 genes in leptin melanocortin pathway
Sponsored by
Central Hospital, Nancy, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Obesity, Child

Eligibility Criteria

6 Months - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: severe obesity with BMI > 3SDS Exclusion Criteria: genetic obesity (Prader Willi syndrome, Bardet Biedl syndrome, X fragile syndrome, Alstrom syndrome) BMI < 3 SDS age < 6 months monogenic non syndromic obesity, with mutation in genes of leptin melanocortin pathway previously diagnosed cushing syndrome

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    severe obese children

    Arm Description

    children with severe obesity with BMI > 3sds

    Outcomes

    Primary Outcome Measures

    frequency of mutations of genes from leptin melanocortin pathway
    Evaluating of the frequency of mutations of 14 genes from leptin melanocortin pathway (LEP, LEPR, POMC, PCSK1, MC3R, MC4R, MRAP2, ADCY3, SIM1, SH2B1, NTRK2, BDNF, KSR2) in a group of french children with severe obesity.

    Secondary Outcome Measures

    Clinical characteristics of children with severe obesity followed in CHRU of Nancy
    Description of the clinical characteristics : height in cm BMI
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description of the clinical characteristics :thyroid function (TSH T3 T4)
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description of the clinical characteristics : IGF1 levels
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description of the clinical characteristics :BMI in kg/m²
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description of the clinical characteristics : weight in kg
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description of the clinical characteristics : bone age (X ray of the left hand)
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description of the clinical characteristics : metabolic profile
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description of the clinical characteristics : leptin level
    Penetrance of mutations from leptin melanocortin pathway
    Evaluation of the penetrance of mutation from leptin melanocortin pathway, that is to say the percentage of obesity in mutation carrier
    effect of age, sex, country of birth on mutations' penetrance.
    Evaluation of the effect of age, sex, country of birth on mutations' penetrance.
    Clinical characteristics of children with severe obesity followed in CHRU of Nancy
    Description of Clinical characteristics of children with severe obesity followed in CHRU of Nancy : weight in kg Description of the clinical characteristics :
    Clinical characteristics of children with severe obesity followed in CHRU of Nancy
    Description of the clinical characteristics :BMI in kg/m²

    Full Information

    First Posted
    June 12, 2023
    Last Updated
    July 3, 2023
    Sponsor
    Central Hospital, Nancy, France
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05938335
    Brief Title
    Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood.
    Acronym
    OBEGEN
    Official Title
    Results of Sequencing of a Large Panel of Genes From Leptin Melanocortin Pathway in Children Suffering From Severe Obesity
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 1, 2023 (Anticipated)
    Primary Completion Date
    October 1, 2024 (Anticipated)
    Study Completion Date
    January 1, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Central Hospital, Nancy, France

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    About 380 million children and adolescents suffer from overweight and obesity at the global level. Obesity results from the interplay between biological (sex, age, fetal programming, gut microbiota, epigenetics, and genetics) and environmental factors (e.g., unhealthy diet, physical inactivity, stress). Mutations in genes from leptin melanocortin pathway are involved in "non syndromic monogenic obesity", characterized by severe early onset obesity, hyperphagia and endocrine deficiencies. Exact frequencies of mutation in these genes are not precisely evaluated in french children with severe obesity. Moreover new treatment, such seltmelanotide are avalaible in case of certain mutation, leading to a significative weight loss in treated patients.
    Detailed Description
    Obesity is a global health concern that affected more than 650 million adult people and more than 380 million children and adolescents worldwide, with no signs of slowing down despite major investments in health policy. Obestiy is a multifactorial disease, but 40 to 75% of body mass index (BMI) variation is explained by genetic factors. Mutations in genes from leptin melanocortin pathway lead to "non syndromic monogenic obesity", characterized by severe early onset obesity, hyperphagia and endocrine deficiencies. This pathway plays a central role in regulating mammalian food intake, energy expenditure and body weight regulation. Somes genes are well characterized such LEP gene, LEPR gene, or MC4R but others have been recently described as ADCY3, SIM1, SH2B1, NTRK2, BDNF, KSR2. The frequency of these mutations are not precisely estimated in a group of french children with severe obesity. Moreover, a precocious identification of these mutations, could afford, in certain case the possibility of a efficient treatment with setmelanotide, leading to a significant weight loss in treated patients.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Obesity, Child

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    100 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    severe obese children
    Arm Type
    Experimental
    Arm Description
    children with severe obesity with BMI > 3sds
    Intervention Type
    Genetic
    Intervention Name(s)
    sequencing of a panel of 14 genes in leptin melanocortin pathway
    Intervention Description
    sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
    Primary Outcome Measure Information:
    Title
    frequency of mutations of genes from leptin melanocortin pathway
    Description
    Evaluating of the frequency of mutations of 14 genes from leptin melanocortin pathway (LEP, LEPR, POMC, PCSK1, MC3R, MC4R, MRAP2, ADCY3, SIM1, SH2B1, NTRK2, BDNF, KSR2) in a group of french children with severe obesity.
    Time Frame
    1 year
    Secondary Outcome Measure Information:
    Title
    Clinical characteristics of children with severe obesity followed in CHRU of Nancy
    Description
    Description of the clinical characteristics : height in cm BMI
    Time Frame
    1 year
    Title
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description
    Description of the clinical characteristics :thyroid function (TSH T3 T4)
    Time Frame
    1 year
    Title
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description
    Description of the clinical characteristics : IGF1 levels
    Time Frame
    1 year
    Title
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description
    Description of the clinical characteristics :BMI in kg/m²
    Time Frame
    1 year
    Title
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description
    Description of the clinical characteristics : weight in kg
    Time Frame
    1 year
    Title
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description
    Description of the clinical characteristics : bone age (X ray of the left hand)
    Time Frame
    1 year
    Title
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description
    Description of the clinical characteristics : metabolic profile
    Time Frame
    1 year
    Title
    Clinical characteristics of children with mutations of leptin melanocortin pathway
    Description
    Description of the clinical characteristics : leptin level
    Time Frame
    1 year
    Title
    Penetrance of mutations from leptin melanocortin pathway
    Description
    Evaluation of the penetrance of mutation from leptin melanocortin pathway, that is to say the percentage of obesity in mutation carrier
    Time Frame
    1 year
    Title
    effect of age, sex, country of birth on mutations' penetrance.
    Description
    Evaluation of the effect of age, sex, country of birth on mutations' penetrance.
    Time Frame
    1 year
    Title
    Clinical characteristics of children with severe obesity followed in CHRU of Nancy
    Description
    Description of Clinical characteristics of children with severe obesity followed in CHRU of Nancy : weight in kg Description of the clinical characteristics :
    Time Frame
    1 year
    Title
    Clinical characteristics of children with severe obesity followed in CHRU of Nancy
    Description
    Description of the clinical characteristics :BMI in kg/m²
    Time Frame
    1 year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Months
    Maximum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: severe obesity with BMI > 3SDS Exclusion Criteria: genetic obesity (Prader Willi syndrome, Bardet Biedl syndrome, X fragile syndrome, Alstrom syndrome) BMI < 3 SDS age < 6 months monogenic non syndromic obesity, with mutation in genes of leptin melanocortin pathway previously diagnosed cushing syndrome
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Emeline RENARD
    Phone
    +33383154500
    Email
    e.renard@chru-nancy.fr

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood.

    We'll reach out to this number within 24 hrs